Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 333

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Open access
Werbel, William A., Boyarsky, Brian J., Ou, Michael T., Massie, Allan B., Tobian, Aaron A.R., Garonzik-Wang, Jacqueline M., Segev, Dorry L. · 2021 · Annals of Internal Medicine

Abstract

Letters15 June 2021Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case SeriesFREEWilliam A. Werbel, MD, Brian J. Boyarsky, MD, PhD, Michael T. Ou, BS, Allan B. Massie, PhD, Aaron A.R. Tobian, MD, PhD, Jacqueline M. Garonzik-Wang, MD, PhD, and Dorry L. Segev, MD, PhDWilliam A. Werbel, MDJohns Hopkins University School of Medicine, Baltimore, MarylandSearch for more papers by this author, Brian J. Boyarsky, MD, PhDJohns Hopkins University School of Medicine, Baltimore, MarylandSearch for more papers by this author, Michael T. Ou, BSJohns Hopkins University School of Medicine, Baltimore, MarylandSearch for more papers by this author, Allan B. Massie, PhDJohns Hopkins University School of Medicine, Baltimore, MarylandSearch for more papers by this author, Aaron A.R. Tobian, MD, PhDJohns Hopkins University School of Medicine, Baltimore, MarylandSearch for more papers by this author, Jacqueline M. Garonzik-Wang, MD, PhDJohns Hopkins University School of Medicine, Baltimore, MarylandSearch for more papers by this author, and Dorry L. Segev, MD, PhDJohns Hopkins University School of Medicine, Baltimore, MarylandSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L21-0282 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: The antibody response after 2 doses of an mRNA vaccine against SARS-CoV-2 is excellent in the general population (1), but the response is different in recipients of solid organ transplants. For example, we have found markedly attenuated antibody responses in transplant recipients after 2 doses of an mRNA vaccine against SARS-CoV-2 (2). In addition, reports of COVID-19 breakthrough infections in vaccinated transplant recipients (3) have prompted interest in administering additional doses of vaccine.Objective: To describe antibody responses and vaccine reactions in recipients of solid organ transplants who had a suboptimal response to standard vaccination and subsequently received a third dose of vaccine between 20 March 2021 and 10 May 2021.Case Series: This study was approved by the Johns Hopkins institutional review board, and participants provided informed consent.Thirty patients reported receiving a third dose of vaccine (Table 1). Their median age was 57 years (interquartile range [IQR], 44 to 62 years), 17 were women, and 1 identified as non-White. None of the patients reported an illness before vaccination that was consistent with COVID-19 or a positive result on polymerase chain reaction (PCR) assay. In 25 patients, maintenance immunosuppression included tacrolimus or cyclosporine plus mycophenolate. In addition, corticosteroids were used for 24 patients, sirolimus for 1, and belatacept for 1. The median time between transplantation and initial vaccination was 4.5 years (IQR, 2.3 to 10.5 years). During the initial vaccination, 57% of the 30 patients received 2 doses of the 162b2 vaccine (Pfizer/BioNTech), and 43% received 2 doses of the mRNA-1273 vaccine (Moderna).Table 1 Vaccines Administered, Antibody Responses, Patient Characteristics, and Organs TransplantedWe tested all patients for antibodies against the spike protein at a median of 9 days (IQR, 2 to 33 days) before they received their third dose of vaccine; 24 patients had negative antibody titers, and 6 patients had low-positive antibody titers. Patients received the third dose of vaccine a median of 67 days (IQR, 54 to 81 days) after the second dose of their initial vaccine series; 15 patients received the Ad26.COV2.S vaccine (Johnson & Johnson/Janssen), 9 received the mRNA-1273 vaccine (Moderna), and 6 received the 162b2 vaccine (Pfizer/BioNTech).We repeated antibody testing a median of 14 days (IQR, 14 to 17 days) after the third dose of vaccine. Of the 6 patients with low-positive antibody titers before the third dose, all had high-positive antibody titers after the third dose. In contrast, of the 24 patients with negative antibody titers before the third dose, only 6 (25%) had high-positive antibody titers after the third dose. Two (8%) had low-positive antibody titers, and 16 (67%) remained negative.Twenty-three patients completed a questionnaire 7 days after receiving their third dose that asked about specific vaccine reactions (Table 2). Fifteen patients reported mild or moderate local reactions, and 1 reported severe arm pain. The most frequent systemic reaction was mild or moderate fatigue in 14 participants; 1 patient reported severe headache, and 1 patient reported severe myalgia. No patient reported fever, and we did not observe any anaphylactoid reactions or neurologic complications. One heart transplant recipient had biopsy-proven, antibody-mediated rejection 7 days after her third dose of vaccine in the setting of acute volume overload. She did not experience an increase in her titer of antibodies against the spik

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/l21-0282

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 333

Metadata

Authors
Werbel, W. A., Boyarsky, B. J., Ou, M. T., Massie, A. B., Tobian, A. A. R., Garonzik-Wang, J. M., & Segev, D. L.
Venue
Annals of Internal Medicine
Published
2021-09
Volume
174
Issue
9
Pages
1330-1332
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W3168511545
Cited by
333
References
4
FWCI
23.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. https://app.cochat.ai/papers/10.7326/l21-0282
The paper
Werbel, W. A., Boyarsky, B. J., Ou, M. T., Massie, A. B., Tobian, A. A. R., Garonzik-Wang, J. M., & Segev, D. L. (2021). Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Annals of Internal Medicine. https://doi.org/10.7326/l21-0282

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.